Table 2.
Parameters | Adjusted Analysisa | |||
---|---|---|---|---|
HR | 95% CI | P | ||
Latest CD4 count per mm3 (lagged by 3-months) | >500 | Reference | ||
350–500 | 1.43 | 1.00–2.05 | .05 | |
200–350 | 2.02 | 1.42–2.86 | <.001 | |
100–200 | 3.07 | 2.03–4.66 | <.001 | |
50–100 | 5.35 | 3.19–8.97 | <.001 | |
<50 | 15.44 | 10.34–23.08 | <.001 | |
Cohort | AHOD | Reference | ||
TAHOD | 1.53 | 0.92–2.55 | 0.100 | |
Interaction termb | 0.256b |
Abbreviations: HR, Hazard ratio; TAHOD, TREAT Asia HIV Observational Database; AHOD, Australian HIV Observational Database; CD4 count refers to CD4 T-cell count.
Models were a priori adjusted for fixed covariates, including cohort (TAHOD/AHOD), gender, hepatitis B and C coinfection, HIV exposure category, and prior AIDS; and time-updated covariates including HIV RNA category lagged by 3 months (categorized as <500, 500–10 000, and >10 000 copies/mL), age, on or off cART, calendar year (categorized as earlier than 2000, 2000–2002, 2002–2004, 2004–2006, 2006–2008, and later than 2008) and new AIDS (for mortality endpoint only).
P value is for the interaction term (product of cohort [TAHOD/AHOD] and categorized CD4 count lagged by 3 months), obtained in the adjusted model predicting respective endpoint. Excluding the interaction term from the multivariable model changes the HR for cohort (TAHOD vs. AHOD) to 1.43 (95% CI: 1.02–2.00) for AIDS or death and 0.84 (95% CI: 0.53–1.33) for all-cause mortality.